Boan Biotech Reports Strong Mid-Year Financial Growth

Shandong Boan Biotechnology Company., Limited. Class H (HK:6955) has released an update.

Shandong Boan Biotechnology Co., Ltd. reported a significant revenue increase of 38.9% to RMB362.9 million for the first half of 2024, driven by strong sales growth of its products in China. The company also achieved a substantial 78.6% rise in gross profit, while managing to lower manufacturing costs due to increased production volume and improved manufacturing processes. Despite these gains, the company noted a decrease in R&D expenses as more projects moved into advanced clinical trials.

For further insights into HK:6955 stock, check out TipRanks’ Stock Analysis page.